Melanotan I (Afamelanotide)

Melanotan I (afamelanotide, Scenesse) is a synthetic linear analog of alpha-MSH that stimulates MC1R to increase eumelanin production. Unlike Melanotan II, it is MC1R-selective and does not significantly affect sexual function or appetite. It is FDA and EMA-approved for erythropoietic protoporphyria (EPP).

3 independent Janoshik purity tests cover Melanotan I (Afamelanotide) across 1 vendor.

Category: Dermatology / Approved. Evidence rating: A (strong human clinical data).

Clinical status: FDA-approved (2019) and EMA-approved (2014) for EPP

Afamelanotide selectively agonizes MC1R on melanocytes, stimulating eumelanin synthesis via cAMP/PKA pathway activation. This increases melanin density in the skin, providing photoprotection. It also enhances DNA repair in melanocytes exposed to UV radiation.

Safety considerations: Nausea; Headache; Darkening of moles requires monitoring.

Reviewed by the PeptideAtlas Editorial Team.

Melanotan I (Afamelanotide) — measured properties

Amino-acid sequence[Nle4, D-Phe7]-alpha-MSH
Molecular weight1646.9 Da
Half-life~30 minutes
Production methodsynthetic
Anti-doping statusnot-listed

Melanotan I (Afamelanotide) third-party purity tests

VendorBest tested purity
Imperial Peptides99.4%

Frequently asked questions

Is Melanotan I the same as Melanotan II?

No. Melanotan I (afamelanotide) is MC1R-selective and does not significantly affect sexual function. Melanotan II is non-selective, activating MC1R, MC3R, MC4R, and MC5R, which causes sexual arousal, appetite suppression, and tanning.

What is Melanotan I (Afamelanotide)?

Melanotan I (afamelanotide, Scenesse) is a synthetic linear analog of alpha-MSH that stimulates MC1R to increase eumelanin production. Unlike Melanotan II, it is MC1R-selective and does not significantly affect sexual function or appetite. It is FDA and EMA-approved for erythropoietic protoporphyria (EPP).

How strong is the evidence for Melanotan I (Afamelanotide)?

On the PeptideAtlas A–F scale, Melanotan I (Afamelanotide) is rated A (Strong Evidence). Approved medication with strong human evidence

What is the clinical status of Melanotan I (Afamelanotide)?

FDA-approved (2019) and EMA-approved (2014) for EPP

How does Melanotan I (Afamelanotide) work?

Afamelanotide selectively agonizes MC1R on melanocytes, stimulating eumelanin synthesis via cAMP/PKA pathway activation. This increases melanin density in the skin, providing photoprotection. It also enhances DNA repair in melanocytes exposed to UV radiation.

Coverage on this site: Reducing Benzotriazole and Solvent Hazards in Peptide Synthesis, Melanotan 1: Tanning Peptide with Broad Research Potential.